Afimmune announces successful completion of a Phase I safety study with bioactive lipid DS102 which is targeting NASH and IPF

Afimmune obtains a granted patent covering the use of DS102 to treat fatty liver disorders
November 9, 2015
Afimmune presents late-breaking news abstract on DS102 at the European Association for the Study of the Liver (EASL) International Liver Congress
April 14, 2016
Show all

Afimmune announces successful completion of a Phase I safety study with bioactive lipid DS102 which is targeting NASH and IPF

Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF) .

The Phase I study was a randomised, placebo-controlled, double-blind, single-ascending and multiple dose clinical trial to assess the safety, pharmacokinetics and effect of food on DS102 in 56 healthy volunteers.

The study confirmed that following both single and multiple oral doses over 28 days, DS102 was safe and well tolerated, thereby successfully meeting the study’s primary safety objective. There were no serious adverse events or volunteer discontinuations due to adverse events. In addition, it was observed that the presence of food improved the oral absorption of the compound, a result which will help inform the Phase II dosing regimen of this compound.

Commenting on the results, Afimmune CEO, Dr. John Climax said:

‘The Company welcomes the results of the study which confirmed that DS102 has a very high safety margin in humans. Taken together with positive preclinical results to date, primarily driven by the anti-inflammatory and anti-fibrotic activity of the molecule, the Phase I results pave the way for Phase II studies for DS102 in NASH and other fibrotic conditions such as IPF’.

About Afimmune

Afimmune Limited (Afimmune), headquartered in Dublin, Ireland, is a drug discovery and development company working on inflammatory conditions of the human primary organs including the liver and the lung.

Contacts:
Afimmune: info@Afimmune.com

Updated from DS Biopharma to Afimmune as effective from 22nd August 2016